Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 6/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23832959 | 0.99 | PRMT5 (0.39) | PRMT5WDR77TRPV4NR1H2KAT6A | |
| Hydrochloric Acid SCHEMBL23832958 | 0.99 | PRMT5 (0.39) | PRMT5WDR77TRPV4NR1H2KAT6A | |
| SCHEMBL27015368 | 0.88 | KAT6A (0.41) | PRMT5WDR77NR1H2KAT6ANR1H3 | |
| SCHEMBL23845148 | 0.84 | CA1 (0.39) | TRPV4 | |
| Hydrochloric Acid SCHEMBL23833102 | 0.83 | CA1 (0.41) | TRPV4 | |
| Hydrochloric Acid SCHEMBL23833104 | 0.83 | CA1 (0.41) | TRPV4 | |
| SCHEMBL28737942 | 0.79 | CYP1A2 (0.52) | PRMT5WDR77NR1H2KAT6ANR1H3 | |
| SCHEMBL28737943 | 0.79 | CYP1A2 (0.52) | PRMT5WDR77NR1H2KAT6ANR1H3 | |
| SCHEMBL28738065 | 0.79 | CYP1A2 (0.52) | PRMT5WDR77NR1H2KAT6ANR1H3 | |
| SCHEMBL23833144 | 0.78 | HDAC3 (0.40) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023183607-A1 | CEREBLON LIGANDS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2021188696-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | PRMT5 1448/4885WDR77 1781/4885TRPV4 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.